What SFC Fluidics does

SFC Fluidics, Inc. is an Arkansas-based, privately held medical device company that develops microfluidic drug delivery platforms for diabetes care. It operates as a subsidiary within The VIC Tech ecosystem from its headquarters at 534 West Research Center Boulevard, Suite 260, Fayetteville, Arkansas, with a headcount of 11-50 employees. The company is led by CEO Anthony Cruz and was founded in 2003.

SFC Fluidics' product portfolio centers on two interconnected wearable patch pump platforms: the PANDA System, a next-generation insulin patch pump emphasizing dosing accuracy, a compact form factor, and a safety-enhancing dispense confirmation sensor, and the GEMINI System, a dual-reservoir variant that delivers two drugs (such as insulin and a second hormone) with equivalent accuracy and precision, expanding into multi-drug therapies including a Gemini-DHAP dual hormone artificial pancreas pod. The underlying technology is proprietary microfluidics, which the company positions as delivering industry-leading dosing accuracy versus incumbents such as Omnipod Dash. The company also developed an Alternate Controller Enabled (ACE) insulin delivery pod designed for interoperability with third-party Automated Insulin Delivery systems.

SFC Fluidics generates no commercial revenue today; its devices are labeled 'For Investigational Use Only' and are not cleared for sale in the USA or EU. Capital sources to date include a $2 million NIH SBIR Phase II grant (July 2023) for the Gemini-DHAP program and an SEC Form D exempt securities offering of $650,000 (October 2025). The go-to-market plan is an enterprise field sales motion targeting endocrinologists, diabetes care centers, and healthcare systems post-clearance, with two core strategic partnerships supporting the platform: Diabeloop SA (US AID integration, January 2021) and Duracell (power solutions collaboration, March 2024). The company received FDA Breakthrough Device Designation for its insulin pod in December 2020 and refreshed its brand and digital presence in March 2026 ahead of an anticipated commercial pathway.

Name

SFC Fluidics

Legal name

SFC Fluidics Inc.

Website

https://sfc-fluidics.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

SFC Fluidics is a privately held, pre-commercial medical device company developing microfluidic patch pump platforms (PANDA insulin pump and GEMINI dual-hormone system) for diabetes patients, operating under FDA investigational-use status within the VIC Tech ecosystem.

Ownership category

akta.pro rank

Product category

Wearable Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)

akta.pro secondary industries

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Insulin Pumps & Patch Pumps (HLAHAIAG)

Keywords

• Microfluidic drug delivery
• Insulin patch pumps
• Wearable medical devices
• Diabetes management devices
• Dual hormone delivery

Headquarters

HQ city

Fayetteville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales (Planned): The company is developing wearable drug delivery devices (PANDA and GEMINI systems) for diabetes care. Currently in pre-commercialization stage with devices designated for investigational use only. Revenue expected to be generated through hardware sales of patch pumps and potentially recurring revenue from consumables and accessories once regulatory clearance is obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SFC Fluidics develops and manufactures wearable microfluidic drug delivery devices for diabetes care. Its core offerings are the PANDA System, a next-generation insulin patch pump with industry-leading dosing accuracy and a safety-enhancing dispense confirmation sensor, and the GEMINI System, a dual-reservoir wearable pump for simultaneous delivery of two drugs (e.g., dual hormone artificial pancreas applications). Devices are currently for investigational use only and not yet cleared for sale in the USA or EU.

Product overview

SFC Fluidics offers a portfolio of two interconnected wearable drug delivery systems: the PANDA System (insulin-only patch pump) and the GEMINI System (dual hormone variant). Both products leverage advanced microfluidic technology for precise insulin delivery, with the GEMINI expanding into multi-drug therapies by adding a secondary reservoir. The systems are designed for diabetes care with safety-enhancing features and dosing accuracy, and are part of The VIC Tech ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• PANDA System: Next-generation patch pump for insulin delivery with precision dosing, compact design, and safety-enhancing dispense confirmation sensor.
• GEMINI System

Products and services

• PANDA System

Quantifiable outcome

• More precise dosing than existing alternatives
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• DuracellcoreStrategic or Co-development Partner · 18 March 2024SFC Fluidics collaborated with Duracell to integrate long-lasting, efficient power solutions into cutting-edge wearable drug delivery systems targeting diabetes treatment. This partnership addresses power management challenges in wearable medical devices, enhancing reliability and user experience for patients using SFC's PANDA and GEMINI systems.
• Diabeloop SAcoreStrategic or Co-development Partner · 7 January 2021SFC Fluidics partnered with Diabeloop, a pioneer in therapeutic artificial intelligence, to integrate SFC's ACE insulin delivery pod into Diabeloop's Automated Insulin Delivery (AID) solution. This development agreement for the United States market combines SFC's hardware expertise with Diabeloop's AI-driven therapeutic algorithms to create a comprehensive diabetes management solution.
• The VIC TechflagshipOthersSFC Fluidics is part of The VIC Tech ecosystem. VIC Tech appears to be the parent company or organizational umbrella providing operational support and resources to SFC Fluidics and potentially other portfolio companies.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Insulet Corporation: Insulet's Omnipod is the dominant tubeless patch pump for insulin delivery. SFC's PANDA directly targets this category with claims of superior dosing accuracy vs. Omnipod Dash, making Insulet the most direct competitive comparison.
• Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ AID is a leading interoperable insulin pump that integrates with multiple CGMs and algorithms. Comparable as a connected, interoperable pump competitor targeting the same T1D patient segment.

Broad incumbents

• Medtronic (Diabetes): Medtronic's MiniMed insulin pump portfolio and closed-loop 780G system set the incumbent standard in insulin delivery and AID. As a large diversified medtech incumbent with deep payor access, it represents both a competitive benchmark and potential strategic acquirer for SFC's pump platform.
• Dexcom: Dexcom's G6/G7 CGM is the leading continuous glucose monitor and a key sensor partner for any AID system, including those integrating SFC's ACE pump. Comparable as a broad incumbent whose technology ecosystem SFC's device must interoperate with.
• Abbott Diabetes Care: Abbott's FreeStyle Libre is the dominant CGM globally and increasingly integrated into AID ecosystems. Comparable as a broad diabetes device incumbent whose CGM platform complements competing pump offerings to SFC's portfolio.

Emerging players

• Beta Bionics: Beta Bionics developed the iLet bionic pancreas, a dual-hormone (insulin + glucagon) automated delivery system—the closest direct analog to SFC's GEMINI-DHAP in the dual-hormone artificial pancreas category.
• Bigfoot Biomedical: Bigfoot is developing smart pump and connected pen systems for diabetes management. Comparable as an emerging player in next-generation insulin delivery targeting the same patient base as SFC's PANDA.
• SOOIL Development: SOOIL produces the DANA Diabecare insulin pump line, an Asian-market patch and tubed pump competitor. Comparable as a direct patch pump alternative to SFC's PANDA in international diabetes care markets.
• EOFlow: EOFlow manufactures the EOPatch, a disposable tubeless patch pump for insulin delivery. Directly comparable as a patch pump competitor targeting the same form factor and patient use case as PANDA.

Others

• Diabeloop SA: Diabeloop is SFC's announced AID partner and supplies the algorithmic controller into which SFC's ACE pod integrates. Comparable as an ecosystem participant and adjacent player in the closed-loop insulin delivery stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/sfcfluidics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SFC Fluidics